Beryllium, LLC Overview
Pro stress-test →Beryllium, LLC is a specialized drug discovery contract research organization (CRO) headquartered in Bedford, Massachusetts. The company provides research services and collaborative drug discovery platforms focused on protein engineering, expression and purification, functional biology, and structure-based drug design. Now a subsidiary of UCB (acquired June 2017), Beryllium serves leading pharmaceutical, biotechnology, and academic partners.
Strategic Profile
Pro stress-test →Beryllium's competitive advantage lies in its biology-first, target-centric approach and deep expertise in gene-to-function services. The company leverages its proximity to Boston's biotech ecosystem and maintains a history of successful collaborations with major pharma players. As part of UCB, Beryllium's platform supports discovery programs in immune and central nervous system diseases.
Competitive Landscape
Pro stress-test →Beryllium competes with other specialized drug discovery CROs and contract research organizations serving pharma and biotech clients. Key competitors include Envigo, Charles River Laboratories (preclinical services), and smaller regional CROs. Beryllium's advantage is its deep structural biology expertise and proven track record with major pharma clients, though it operates as a subsidiary with limited independent brand visibility.
Industry Context
Beryllium, LLC operates in Drug discovery contract research organizations.
Key facts
Founded: 1999 · Headquarters: Bedford, MA, United States · Employees: 28 · Revenue: $1M–$10M (estimated) · Market cap: N/A